Apr 19 |
Life Science Cares Launches in Switzerland
|
Apr 17 |
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
|
Mar 14 |
Earnings Scheduled For March 14, 2024
|
Mar 1 |
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
|
Jan 8 |
Molecular Partners says data from projected therapeutically active doses of MP0533 from Phase 1/2a trial to be presented in H1
|
Jan 7 |
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
|
Jan 5 |
Molecular Partners, Orano to collaborate on RDT therapies for cancer
|
Jan 5 |
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
|
Dec 14 |
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
|
Nov 14 |
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
|